Loading...
01/11 11:29
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerns: declining revenue and operating losses in the healthcare segment, significant risk from heavy Bitcoin investments, legal expenses from a DOJ settlement, and reliance on equity issuance, which could dilute shareholder value. While there is a positive Bitcoin yield, the volatility and risks associated with Bitcoin, combined with a weak healthcare business performance, outweigh the positives. The Q&A session did not alleviate these concerns, as management's optimism about Bitcoin adoption does not mitigate the financial and operational risks. Overall, these factors suggest a negative stock price reaction.
Total revenues in Q2 2025 $8.2 million, which was down compared to the second quarter of 2024 due to the continued phase-in of the 2024 CMS rate announcement that impacted reimbursement for positive PAD patients, and which is resulting in decreased usage of our device at some of our customers.
Operating expenses for Q2 2025 $10.3 million, which includes $1.9 million in noncash stock-based compensation expense and $0.5 million of legal expenses related to the DOJ settlement agreement in principle pertaining to a civil investigative demand.
Loss from operations $1.2 million for Q2 2025.
Net income for Q2 2025 $66.9 million or $5.71 per basic share and $5.04 per fully diluted share, driven by a net unrealized gain of $83.8 million from the change in fair value of Bitcoin holdings.
Cash, cash equivalents and restricted cash $13.6 million as of June 30, 2025.
Bitcoin acquired in Q2 2025 1,444 Bitcoin at a total cost of $149.6 million or $103,581 per Bitcoin.
Bitcoin holdings as of June 30, 2025 4,636 Bitcoin valued at $496.9 million.
Subsequent Bitcoin acquisition post-Q2 385 Bitcoin at a total cost of $45.8 million or $119,090 per Bitcoin, bringing total holdings to 5,021 Bitcoin valued at $586.2 million as of July 31, 2025.
Capital markets activity in Q2 2025 Issued approximately 4.1 million shares for net proceeds of $156.6 million.
Year-to-date Bitcoin yield through July 31, 2025 31.3%, translating into a Bitcoin dollar gain of $84 million.
CardioVanta: Formation of a wholly owned subsidiary focused on early detection of heart failure and cardiac arrhythmia. It will operate as a high-margin SaaS business model and seek capital from outside investors to validate its long-term value and fund its modest initial capital needs.
Cardiac technology and care systems: The markets for early detection of heart failure and cardiac arrhythmia monitoring are estimated to be in the multibillion-dollar range and are projected to grow substantially due to rising cardiovascular disease, technology advancements, and the aging population.
Bitcoin operations: Purchased approximately $195 million of Bitcoin during the quarter, holding a total of $586 million. Achieved a 31.3% Bitcoin yield year-to-date through July 31, 2025, translating into a Bitcoin dollar gain of $84 million.
Health care business cash generation: Generated record cash of $24 million in 2024, despite facing headwinds in 2025 due to CMS rate changes impacting device usage.
Bitcoin treasury strategy: Targeting 10,000 Bitcoin by year-end 2025, 42,000 by year-end 2026, and 105,000 by year-end 2027. Exploring financing options to meet these targets, including issuing low-interest, long-duration debt and leveraging operating cash flow from the health care business.
Stockholder value: Actively exploring accretive opportunities to unlock value for stockholders, including proposals to raise capital efficiently and pursue long-term Bitcoin acquisition strategy.
Bitcoin Treasury Strategy: The company is heavily investing in Bitcoin, with plans to acquire significant amounts by leveraging debt and issuing equity. This strategy exposes the company to risks associated with Bitcoin's price volatility, regulatory scrutiny, and potential liquidity issues if Bitcoin prices drop significantly.
Health Care Business Performance: Revenues in Q2 2025 were down compared to the previous year due to changes in CMS reimbursement rates, which impacted the usage of the company's PAD device. This decline in revenue poses a challenge to the company's ability to generate cash flow from its health care operations.
DOJ Settlement: The company is incurring legal expenses related to a settlement agreement with the Department of Justice concerning a civil investigative demand. This could result in financial and reputational risks.
Capital Markets Activity: The company is relying on equity issuances and convertible debt to fund its Bitcoin acquisitions and health care business. This strategy could dilute shareholder value and increase financial leverage, posing risks if market conditions deteriorate.
CardioVanta Subsidiary: The company plans to seek external capital for its new subsidiary focused on cardiac technology. While this could unlock value, it also introduces execution risks and dependency on external funding.
Bitcoin Acquisition Targets: Semler Scientific aims to accumulate 10,000 Bitcoin by year-end 2025, 42,000 by year-end 2026, and 105,000 by year-end 2027. The company is exploring various financing options to meet these targets, including operating cash flow, monetizing healthcare investments, issuing convertible bonds, and accretively issuing common stock.
Capital Flexibility for Bitcoin Strategy: Proposals 3 and 4 in the upcoming annual meeting aim to provide financial flexibility to raise capital efficiently for the Bitcoin acquisition strategy. This includes enabling access to a broader range of capital instruments such as preferred equity.
CardioVanta Subsidiary Launch: Semler Scientific has launched a wholly owned subsidiary, CardioVanta, focused on early detection of heart failure and cardiac arrhythmia. The subsidiary will operate as a high-margin SaaS business model and seek external capital to fund its modest initial capital needs. The markets for these technologies are estimated to be in the multibillion-dollar range and are projected to grow substantially.
Healthcare Business Growth: The company plans to launch several new products in markets larger than its current PAD market. These new businesses will be housed under CardioVanta. The healthcare business is expected to generate free cash flow to support Bitcoin acquisitions.
Bitcoin Yield and Financial Performance: Year-to-date through July 31, 2025, Semler Scientific generated a 31.3% Bitcoin yield, translating into a Bitcoin dollar gain of $84 million. The company plans to continue leveraging its healthcare business and low-interest, long-duration debt to amplify Bitcoin exposure.
The selected topic was not discussed during the call.
The earnings call reveals several concerns: declining revenue and operating losses in the healthcare segment, significant risk from heavy Bitcoin investments, legal expenses from a DOJ settlement, and reliance on equity issuance, which could dilute shareholder value. While there is a positive Bitcoin yield, the volatility and risks associated with Bitcoin, combined with a weak healthcare business performance, outweigh the positives. The Q&A session did not alleviate these concerns, as management's optimism about Bitcoin adoption does not mitigate the financial and operational risks. Overall, these factors suggest a negative stock price reaction.
The earnings call highlights a strong focus on Bitcoin acquisitions, which exposes the company to volatility and regulatory risks. Despite cash generation and Bitcoin gains, the healthcare business faces challenges and lacks clear growth guidance. The $500 million ATM program and convertible notes increase financial leverage. The Q&A session reveals concerns about unclear management responses and potential declines in healthcare revenue. These factors, along with the economic and competitive pressures, suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8%.
The earnings call highlights significant financial struggles, including a 44% revenue decline, operational losses, and liquidity concerns. Despite ambitious Bitcoin acquisition plans, the volatility poses financial risks. Regulatory issues add uncertainty, and the management's vague future outlook further exacerbates investor concerns. The overall sentiment is strongly negative, with potential stock decline exceeding -8%.
The company's earnings call presents mixed signals. While there are strong positives like record cash generation, significant Bitcoin holdings, and EPS exceeding expectations, there are also concerns. The absence of a shareholder return plan, potential regulatory risks, and market risks associated with Bitcoin introduce uncertainties. Moreover, management's lack of clarity on 2025 expectations and the reliance on Bitcoin performance pose potential downsides. The convertible note offering and market capitalization growth are positive, but the overall sentiment remains neutral due to the balance of risks and opportunities.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
